



# BAFNA PHARMACEUTICALS LIMITED

Regd. Office. No.299, Thambu Chetty Street, Chennai-600 001. Tel.No. 044-42677555 / Fax No. 044-42677599

With Global Success, **BAFNA PHARMACEUTICALS LIMITED** has now entered the domestic arena by acquiring a PRESTIGIOUS and a SUCCESSFUL, Time Tested 40 year old brand 'RARICAP' formerly marketed by M/s Johnson and Johnson Limited and is determined to continue the legacy of 'RARICAP'.

Raricap\* Forte




Raricap\*



Raricap\* L



Raricap\* Combi



## UNAUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 30th JUNE 2011

(Rs. in Lakhs)

| No | PARTICULARS  | Quarter Ended             |                           | Year Ended              |
|----|--|---------------------------|---------------------------|-------------------------|
|    |  | 30.06.2011<br>(Unaudited) | 30.06.2010<br>(Unaudited) | 31.03.2011<br>(Audited) |
| 1  | <b>INCOME</b>  |                           |                           |                         |
| a  | Sales  | 3162.48                   | 2145.33                   | 10130.32                |
| b  | Other Operating Income   | 0.00                      | 0.00                      | 0.00                    |
|    | <b>Total Income (a+b)</b>  | <b>3162.48</b>            | <b>2145.33</b>            | <b>10130.32</b>         |
| 2  | <b>EXPENDITURE</b>   |                           |                           |                         |
| a  | (Increase) / Decrease in Stock in Trade & Work in Progress                               | (307.32)                  | (14.82)                   | (243.43)                |
| b  | Consumption of Raw materials   | 2799.57                   | 1661.11                   | 8627.42                 |
| c  | Purchase of Traded Goods   | 0.00                      | 0.00                      | 0.00                    |
| d  | Employee Cost  | 120.67                    | 73.74                     | 309.13                  |
| e  | Depreciation   | 73.23                     | 43.69                     | 226.59                  |
| f  | Other Expenditure  | 87.37                     | 88.24                     | 319.03                  |
|    | <b>Total</b>   | <b>2773.52</b>            | <b>1851.96</b>            | <b>9238.74</b>          |
| 3  | <b>Profit from Operations before Other Income, Interest and Exceptional Items (1-2)</b>  | <b>388.96</b>             | <b>293.37</b>             | <b>891.58</b>           |
| 4  | Other Income   | 5.95                      | 1.92                      | 62.10                   |
| 5  | Profit before Interest and exceptional Items (3+4)                                       | 394.91                    | 295.29                    | 953.68                  |
| 6  | Interest & Bank Charges  | 188.50                    | 122.80                    | 429.63                  |
| 7  | Profit(+)/Loss(-) after Interest but before Tax  |                           |                           |                         |
|    | Exceptional items (5-6)  | 206.41                    | 172.49                    | 524.05                  |
| 8  | Exceptional items  | 12.57                     | 12.98                     | 50.28                   |
| 9  | <b>Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)</b>                       | <b>193.84</b>             | <b>159.51</b>             | <b>473.77</b>           |
| 10 | Tax Expenses   | 0.00                      | 0.00                      | 167.55                  |
| 11 | <b>Net Profit(+)/Loss(-) from Ordinary Activities After Tax (9-10)</b>                   | <b>193.84</b>             | <b>159.51</b>             | <b>306.22</b>           |
| 12 | Extraordinary Items  | 0.00                      | 0.00                      | 0.00                    |
| 13 | <b>Net Profit(+)/Loss(-) for the period (11-12)</b>                                      | <b>193.84</b>             | <b>159.51</b>             | <b>306.22</b>           |
| 14 | <b>Paid up Equity Share Capital (Rs.)</b>  | <b>1748.13</b>            | <b>1598.13</b>            | <b>1748.13</b>          |
|    | <b>Face Value of the Share (Rs.)</b>   | <b>10.00</b>              | <b>10.00</b>              | <b>10.00</b>            |
| 15 | Reserves excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year | -                         | -                         | 3368.06                 |
| 16 | Earnings per Share (EPS) :   |                           |                           |                         |
| a  | Basic and diluted EPS Before Extraordinary Item  | 1.11                      | 0.91                      | 1.75                    |
| b  | Basic and diluted EPS After Extraordinary Items  | 1.11                      | 0.91                      | 1.75                    |
| 17 | <b>Public Share Holding :</b>  |                           |                           |                         |
|    | Number of Shares   | 10421345                  | 8138883                   | 10283853                |
|    | Percentage of Share Holding  | 59.61                     | 59.83                     | 58.83                   |
| 18 | <b>Promoters and promoter group</b>  |                           |                           |                         |
| a  | Pledged/Encumbered   |                           |                           |                         |
|    | Number of Shares   | 850000                    | 400000                    | 450000                  |
|    | Percentage of shares (as a % of the total share holding of promoter and promoter group)  | 12.04                     | 5.10                      | 6.25                    |
|    | Percentage of shares (as a % of the total share capital of the company)                  | 4.86                      | 2.50                      | 2.57                    |
| b  | Non-encumbered   |                           |                           |                         |
|    | Number of Shares   | 6209990                   | 7442452                   | 6747482                 |
|    | Percentage of shares (as a % of the total share holding of promoter and promoter group)  | 87.96                     | 94.90                     | 93.75                   |
|    | Percentage of shares (as a % of the total share capital of the company)                  | 35.53                     | 46.57                     | 38.60                   |

### NOTES

- The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 10th August 2011.
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The figures for the previous periods have been regrouped wherever necessary.
- Status of investor Complaints:
 

|  |     |
|--|-----|
| Opening balance  | NII |
| Pending at the beginning of the quarter                        | NII |
| No. of complaints received and disposed off during the quarter | NII |
| Complaints pending at the end of the quarter                   | NII |

Place : Chennai  
Date : 10.08.2011

For and on behalf of the Board of Directors,  
Sd/-  
**BAFNA MAHAVEER CHAND**  
Managing Director